## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

LEE et al.

Appl. No.: 10/567,381 (National Phase of PCT/US2004/002702)

For: Nogo Receptor Antagonists

I.A. Filed: January 30, 2004

Confirmation No.: 9649

Art Unit: To be assigned

Examiner: To be assigned

Atty. Docket: 2159.0430002/EJH/SAC

## Third Supplemental Information Disclosure Statement Filing under 37 C.F.R. § 1.97(b)

Mail Stop PCT

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying Forms, PTO/SB/08A and PTO/SB/08B, are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Third Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Second Supplemental Information Disclosure Statement filed on August 23, 2006 in connection with the above-captioned application.

## Copies of documents FP17, FP18, and NPL37-NPL39 are submitted.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may

- 2 -

LEE et al. Appl. No. 10/567,381

not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return copies of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Hanne A. Caul

Shannon A. Carroll, Ph.D. Attorney for Applicants Registration No. 58,240

Date: Member 16, 2001
1100 New York Avenue, N.W. Washington, D.C. 20005-3934

(202) 371-2600

601096v1\_1.DOC

Atty. Dkt. No. 2159.0430002/EJH/SAC

Equivalent of Form PTO/SB/084. (07-05)
Approved for use through 07/31/2006
U.S. Patient and Trademsek Office vill S. PERATIMENT OF CAUSAGEDE

Substitute for form 1449/PTO	Complete	Complete if Known	
THIRD SUPPLEMENTAL	Application Number	10/567,381 (National Phase of PCT/US2004/002702)	
INFORMATION DISCLOSUR	E. Int'l. Filing Date	January 30, 2004	
STATEMENT BY APPLICAN		LEE, Daniel H.S.	
(Use as many sheets as necessary)	Art Unit	To be assigned	
(ose as many success as necessary)	Examiner Name	To be assigned Sandra Wege	
Sheet 1 of 1	Attorney Docket Number	2159.0430002/EJH/SAC	

	U.S. PATENT DOCUMENTS				
Examiner Cite Initials No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document		
Intitions	140.	Number-Kind Code <sup>2 (If Kzowa)</sup>	MM-DD-YYYY	Applicant of Cited Document	
-					
	l				
1	1	1			

FOREIGN PATENT DOCUMENTS				
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or
		Country Code' Number' Kind Code' (if known)		Applicant of Cited Document
	FP17	WO 03/002602 A2	01/09/2003	Yeda Research and Development Co., Ltd.
	FP18	WO 03/035687 A1	05/01/2003	Novartis AG et al.

601057v1

Examiner Signature	/Sandra Wegert/	Date Considered	11/04/2010
Signature	, oanara rrogore	Considered	

<sup>\*</sup>EXAMINER: natial if reference considered, whether or not citation is in conformance with MEEP 699. Draw line through citation if not in conformance and not considered, include copy of this form with exect communication to applicant. Applicant's unique citation designation number (opingation and the conformation of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. "Enter Office the Issued the document, by the two-letter code (WIPO Standard ST.3). "For Japanese patent document, the indication of the year of the reign of the Emporer must percede the serial number of the patient comment. "Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. "Applicant is to place a check mark here if English language Translation is attacked."

English anguage (ranslation is attached by 37 CFR 197 and 198. The information is required to obtain or ratial a benefit by the public which is to file (and This collection of information is required by 37 CFR 197 and 198. The information is required to 37 CFR 11.4 This collection is eligible to this 2 house to compete, including gathering, preparing, and submitting the completed application from to the USPTO. Time will vay depending upon the innovicual case. Any comments on the amount of time you require to complete the form and/or suggestions for reducing into burden, should be sent Celler Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO	bstitute for form 1449/PTO Complete If Known	
THIRD SUPPLEMENTAL	Application Number	10/567,381 (National Phase of PCT/US2004/002702)
INFORMATION DISCLOS	RE Int'l Filing Date	January 30, 2004
STATEMENT BY APPLICA		LEE, Daniel H.S.
(Use as many sheets as necessa		To be assigned
,	Examiner Name	To be assigned
Sheet 1 of 1	Attorney Docket Number	2159.0430002/EJH/SAC

	NON PATENT LITERATURE DOCUMENTS	
Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	Т
NPL37	McGee, A. and Strittmatter, S., "The Nogo-66 receptor: focusing myelin inhibition of axon regeneration," <i>Trends Neurosci. 26</i> :193-198, Elsevier Applied Science Publishing (2003)	
NPL38	Supplementary Partial European Search Report for European Patent Application No. 04707073.5, European Patent Office, The Hague, mailed September 5, 2006	
NPL39	Supplementary Partial European Search Report for European Patent Application No. 03785123.5, European Patent Office, The Hague, mailed October 5, 2006	
		-
		L
		l
	No.1 NPL37 NPL38	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published   McGee, A. and Strittmatter, S., "The Nogo-66 receptor: focusing myelin inhibition of axon regeneration," *Trends Neurosci. 26:193-198, Elsevier Applied Science Publishing (2003)

601066v1

Examiner		Date	
Signature	/Sandra Wegert/	Considered	11/04/2010

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

<sup>&</sup>quot;EXAMINES: Initial if reference considered, whether or not clation is in conformance with MEPE 600, Draw line through clation if not in conformance and not considered, include copy of this form with next communication to applicant a include copy of the form with next communication to applicant is to place a check merk here if English language Transition which is to file (and by the Transcollection of information is required to State.) As the information is required to State or retain a benefit by the public which is to file (and by the Transcollection of information is required to State or retain a benefit by the public which is to file (and by the Transcollection of the Information is required to State or the Information in the Information of In